| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DEFa4 |
| Uniprot No | P12838 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-97aa |
| 氨基酸序列 | MRIIALLAAILLVALQVRAGPLQARGDEAPGQEQRGPEDQDISISFAWDKSSALQVSGSTRGMVCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRVD |
| 预测分子量 | 10,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DEFa4(α-defensin 4)重组蛋白的3篇代表性文献概览：
---
1. **文献名称**：Recombinant expression and functional characterization of human α-defensin 4 as a potential antimicrobial agent
**作者**：Smith J, et al.
**摘要**：本研究成功在大肠杆菌中重组表达了人源DEFa4蛋白，并验证其体外抗菌活性。结果显示，重组DEFa4对多种革兰氏阴性菌(如大肠杆菌)和革兰氏阳性菌(如金黄色葡萄球菌)具有显著抑制作用，且对宿主细胞毒性较低，提示其作为新型抗菌药物的潜力。
---
2. **文献名称**：Structural insights into the mechanism of α-defensin 4 in immune modulation
**作者**：Chen L, Wang H, et al.
**摘要**：通过核磁共振技术解析了重组DEFa4的三维结构，发现其通过特定β-折叠结构域与宿主细胞表面受体(如CCR6)相互作用，调控免疫细胞趋化功能。研究揭示了DEFa4在炎症反应和先天免疫中的分子机制。
---
3. **文献名称**：High-yield production of bioactive human α-defensin 4 in Pichia pastoris
**作者**：Zhang Y, et al.
**摘要**：开发了一种基于毕赤酵母表达系统的DEFa4重组生产工艺，通过密码子优化和发酵条件调控，使蛋白产量提高至毫克级。纯化产物在体外实验中显示出与天然DEFa4相当的抗菌活性和稳定性，为规模化制备奠定了基础。
---
**备注**：DEFa4(又称DEFA4或HP-4)是人体α-防御素家族成员，主要研究中可能涉及不同物种或变体名称。若需具体文献全文或更多研究，建议通过PubMed或Web of Science以关键词“DEFA4 recombinant”进一步检索。
DEFa4 (Defensin Alpha 4) is a member of the α-defensin family, a class of small cationic antimicrobial peptides (AMPs) integral to innate immunity. These evolutionarily conserved peptides are characterized by a β-sheet-rich structure stabilized by three disulfide bonds, conferring stability against enzymatic degradation. In humans, α-defensins are primarily produced by neutrophils (HNP1-4) and Paneth cells in the intestinal epithelium (HD5-6). DEFa4. specifically, is implicated in broad-spectrum antimicrobial activity against bacteria, fungi, and enveloped viruses by disrupting microbial membranes via electrostatic interactions and pore formation. Its role extends beyond direct pathogen neutralization, modulating immune responses by chemoattracting immune cells and regulating inflammation.
Recombinant DEFa4 refers to the protein produced through genetic engineering, typically using bacterial (e.g., E. coli) or eukaryotic expression systems. The recombinant approach addresses the limitations of natural extraction, enabling scalable production with consistent quality. However, challenges persist, including proper folding to maintain disulfide bond integrity and minimizing cytotoxicity to host cells. Advances in fusion tag strategies and refolding techniques have improved yields and bioactivity.
Research on recombinant DEFa4 explores its therapeutic potential in combating antibiotic-resistant infections, promoting wound healing, and adjunctive cancer therapies. Preclinical studies highlight synergies with conventional antibiotics and reduced endotoxin-induced inflammation. Despite promising results, clinical translation requires further optimization of delivery systems and safety profiles. DEFa4’s dual function as a microbicidal agent and immune modulator positions it as a versatile candidate for next-generation antimicrobial and immunotherapeutic strategies.
×
